NVP Abliva AB

NeuroVive Pharmaceutical AB Interim Report January - September 2016

STOCKHOLM--(BUSINESS WIRE)--

Regulatory News:

NeuroVive (STO:NVP)

Business operations

Important events July-September 2016

  • NeuroVive completed a 10 percent partial acquisition of its business partner, Isomerase Therapeutics
  • NeuroVive received a request to terminate the Company’s license agreement with Arbutus Biopharma
  • NeuroVive’s strategy for the treatment of mitochondrial disease was published in Nature Communications

Important events after the end of the period

  • The development of CicloMulsion for acute kidney injury was discontinued and as a consequence the value of the subsidiary NeuroVive Asia has been written-down by 50 percent and all previously capitalized expenditure in connection with CicloMulsion has been recognized as an impaired value in the interim report for the third quarter
  • New business model encompassing out-licensing of projects for common indications, as well as proprietary development of orphan indication projects, was communicated
  • Positive preclinical results obtained in an experimental model for non-alcoholic steatohepatitis (NASH), a very serious and common disease for which no medication is currently available
  • In a termination agreement, all rights for NVP018 were returned to NeuroVive from Arbutus Biopharma. NeuroVive also received material manufactured by Arbutus valued at USD 1.5 million

Financial information

Third quarter (July – September 2016 )

  • Net revenues were SEK 0 (0) and other operating income was SEK 16,000 (74,000)
  • Loss before tax was SEK 34,290,000 (53,948,000), for further information see page 6
  • Loss per share* was SEK 0.86 (1.75)
  • Diluted loss per share** was SEK 0.86 (1.75)

First nine months of the year (January-September 2016 )

  • Net revenues were SEK 0 (2,502,000) and other operating income was SEK 90,000 (499,000)
  • Loss before tax was SEK 57,265,000 (83,435,000), for further information see page 6
  • Loss per share* was SEK 1.42 (2.78)
  • Diluted loss per share** was SEK 1.42 (2.78)

* Profit/loss for the period divided by the average number of shares before dilution at the end of the period.

**Profit/loss for the period divided by the average number of shares after dilution at the end of the period.

This information was brought to you by Cision http://news.cision.com

EN
22/11/2016

Underlying

NVPAbliva AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Abliva AB

 PRESS RELEASE
Free
NVP ABLIVA AB

Abliva Announces Positive Interim Analysis of the FALCON Study for KL1...

Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease - Independent committee confirms FALCON study is powered for potential success with both alternative endpoints passing futility- -Committee confirms strong safety profile of KL1333- - Abliva to host conference call and webcast on Friday 19 July at 4:30 pm CET / 10:30 am ET – LUND, Sweden, July 18, 2024 (GLOBE NEWSWIRE) -- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced...

July 18, 2024 1 EN
 PRESS RELEASE
Free
NVP ABLIVA AB

Abliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Di...

Abliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024 LUND, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that it will host a virtual KOL event on Tuesday, May 21, 2024 at 10:00 AM ET / 4:00 PM CET, featuring Amel Karaa, MD (Massachusetts General Hospital), who will discuss the unmet medical need and current treatment landscape for patients with primary mitochondrial disease. There are currently n...

May 13, 2024 1 EN
Sean Conroy
  • Sean Conroy
NVP ABLIVA AB

Abliva - Termination of coverage

Edison Investment Research is terminating coverage on Abliva (ABLI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

03/01/23 March 1, 2023 1 EN
Sean Conroy
  • Sean Conroy
NVP ABLIVA AB

Abliva - IND approved by the FDA, preparing for Ph II/III

With the investigational new drug (IND) application approved by the FDA, Abliva is getting ready for the pivotal Phase II/III trial for its lead drug candidate KL1333, NAD+ modulator expected to increase cellular energy production in primary mitochondrial disorder (PMD) patients. Phase Ia/b data with first findings from treating patients were published in 2021. Abliva is now focused on finalising the regulatory approvals in other countries. Another major focus for the management is to establish ...

01/13/22 January 13, 2022 1 EN
Sean Conroy
  • Sean Conroy
NVP ABLIVA AB

Abliva - IND approved by the FDA, preparing for Ph II/III

With the investigational new drug (IND) application approved by the FDA, Abliva is getting ready for the pivotal Phase II/III trial for its lead drug candidate KL1333, NAD+ modulator expected to increase cellular energy production in primary mitochondrial disorder (PMD) patients. Phase Ia/b data with first findings from treating patients were published in 2021. Abliva is now focused on finalising the regulatory approvals in other countries. Another major focus for the management is to establish ...

01/13/22 January 13, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch